We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
VENCLEXTA (Abbvie Pty Ltd)
Product name
VENCLEXTA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
211 (255 working days)
Active ingredients
venetoclax
Registration type
EOI
Indication
VENCLEXTA in combination with obinutuzumab is now also indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).